SI-BONE posts FY2025 worldwide revenue of USD 200.9 million, up 20%

Reuters
Jan 12
SI-BONE posts FY2025 worldwide revenue of USD 200.9 million, up 20%

SI-BONE reported preliminary and unaudited financial results for the fourth quarter (Q4) and full year (FY) 2025. For Q4 2025, worldwide revenue was between USD 56.2 million and USD 56.3 million, reflecting approximately 15 percent growth. U.S. revenue for the quarter was between USD 53.3 million and USD 53.4 million, representing approximately 14 percent growth. The company reported having approximately 1,640 active physicians in the U.S., an increase of approximately 18 percent. For FY 2025, worldwide revenue was between USD 200.8 million and USD 200.9 million, showing around 20 percent growth. U.S. revenue for the full year was between USD 190.9 million and USD 191.0 million, indicating approximately 21 percent growth. Cash and cash equivalents at the end of Q4 2025 were approximately USD 147.7 million, with net cash generation of about USD 2.0 million in the quarter. These results are preliminary and subject to adjustment following the completion of financial closing and audit procedures.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SI-BONE Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9623396) on January 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10